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Abstract 
Background: Carbapenems are β-lactam antibiotics which are used to treat severe infections caused by multidrug 
resistant Enterobacteriacea. The recent emergence and rapid spread of Enterobacteriaceae resistant to carbapenems 
is a global concern. We undertook a systematic review of the antibiotic susceptibility and genotypic characteristics of 
carbapenem-resistant Enterobacteriaceae in Chinese neonates.
Methods: Systematic literature reviews were conducted (PubMed/Medline, Embase, Wanfang medical online data-
bases, China National Knowledge Infrastructure (CNKI) database) regarding sepsis caused by carbapenem-resistant 
Enterobacteriaceae in Chinese neonates aged 0-30 days.
Results: 17 studies were identified. Eleven patients in the six studies reported the source of infection. Ten patients 
(10/11, 90.9%) were hospital-acquired infections. Genotypic data were available for 21 isolates in 11 studies (20 K. 
pneumoniae, 1 E. coli). NDM-1 was the most frequently reported carbapenem-resistant genotype (81.0%, 17/21). 
Carbapenem-resistant Klebsiella pneumoniae and Escherichia coli were resistant to many antibiotic classes with the 
exception of colistin and fosfomycin. Sequence type 105 (ST105) was the most commonly reported K. pneumoniae 
ST type (30.8%; 4/13), which was from the same hospital in Western China. ST17 and ST20 were the second and third 
most common K. pneumoniae ST type, 23.1% (3/13) and 15.4% (2/13) respectively. The three strains of ST17 are all 
from the same hospital in central China. The two strains of ST20, although not from the same hospital, belong to the 
eastern part of China.
Conclusions: Klebsiella pneumoniae with the NDM-1 genotype was the leading cause of neonatal carbapenem resist-
ant sepsis in China. Hospital acquired infection is the main source of carbapenem resistant sepsis. There is currently no 
licenced antibiotic regimen available to treat such an infection in China. Improved surveillance, controlling nosoco-
mial infection and the rational use of antibiotics are the key factors to prevent and reduce its spread.
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Background
According to the global reports, in 2013, 51.8% of the 6.3 
million children under the age of five died of infectious 
diseases, while 44% (276.1 million) died during the neo-
natal period. Neonatal sepsis is the third leading cause of 
neonatal death, killing 0.421 million neonates worldwide 
in 2013 [1]. The overall incidence of neonatal sepsis in 
four Asian centres (including mainland China, Thailand, 
Macau, and Malaysia) was 26.1 (95% CI 24.5 to 27.8) per 
1000 admissions and Klebsiella spp. was the most com-
mon Gram negative organism causing most deaths [2]. 
Laxminarayan et al. [3] reported that 214 000 of 690, 000 
annual neonatal deaths (31%) associated with sepsis are 
potentially attributable to antimicrobial resistance. Car-
bapenems are beta-lactam antibiotics which are used 
to treat severe infections caused by multidrug resistant 
Enterobacteriaceae, such as Klebsiella pneumoniae (K. 
pneumoniae) and Escherichia coli (E. coli). The recent 
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emergence and rapid spread of Enterobacteriaceae resist-
ant to carbapenems is therefore of global concern [4].
Resistance to carbapenems includes production of 
carbapenemases or a combination of structural muta-
tions and production of other β-lactamases, such as 
extended-spectrum β-lactamase (ESBL) and AmpC 
cephalosporinases. Bacteria that produce carbapene-
mases, enzymes that hydrolyze carbapenems, can break 
down other β-lactam antibiotics including penicillins, 
cephalosporins, and monobactams [5]. Carbapenemases 
can be divided into class A (e.g. K. pneumoniae carbap-
enemase, KPC), class B metallo-β-lactamases [MBLs, e.g. 
New Delhi metallo-β-lactamase (NDM), Verona integrin-
encoded metallo-beta-lactamases (VIM), Imipenem-
resistant Pseudomonas (IMP)] and class D β-lactamases 
(e.g. oxacillinases OXAs). Class C β-lactamases are rarely 
reported [4].
Recent studies suggest that carbapenem resistance is 
increasing in China. A national report using data from 
CHINET (a Chinese antimicrobial resistance surveil-
lance network) has shown that the overall prevalence of 
imipenem-resistant K. pneumoniae increased from 3.0% 
to 20.9% and meropenem-resistance from 2.9% to 24.0% 
between 2005 and 2017. These data included both chil-
dren and adults and most of the samples were from spu-
tum and urine. Among the five children’s hospitals, the 
resistance rate of K. pneumoniae isolated from one hospi-
tal to imipenem was 2.5%, while from the other four hos-
pitals resistance rates ranged from 32.1% to 45.5%. Little 
information was available on age ranges and types of 
samples [6]. This systematic review aimed to summarize 
the current data from both English and Chinese language 
sources on the antibiotic susceptibility and genotypic 
characteristics of carbapenem-resistant Enterobacte-
riaceae (K. pneumoniae and E. coli) causing neonatal sep-
sis in China.
Methods
Definitions
Carbapenem-resistance was defined as resistance to any 
one of meropenem, imipenem, or ertapenem according 
to the US Central Laboratory Standards Institute (CLSI). 
In 2015 the breakpoint was changed from 2010. Labo-
ratories using Enterobacteriaceae minimal inhibitory 
concentration (MIC) interpretive criteria for carbapen-
ems described in M100-S20 (January 2010) performed 
the modified Hodge test (MHT), Carba NP test and/or 
a molecular assay when isolates of Enterobacteriaceae 
were suspicious for carbapenemase production based 
on impipenem or meropenem MICs of 2–4 ug/ml or 
ertapenem MIC of 2 ug/ml in 2015 [7]. Carbapenem-
resistant K. pneumoniae or E. coli sepsis was defined as 
a laboratory confirmed culture of K. pneumoniae or E. 
coli obtained from the blood accompanied with signs and 
symptoms of infection [8]. Neonates were defined as age 
0-30 days [9].
Search strategy and selection criteria
This systematic review was conducted according to the 
Preferred Reporting Items for Systematic Reviews and 
Meta-Analyses guidance (PRISMA) [10]. We searched 
the published literature from PubMed/Medline, Embase, 
China National Knowledge Infrastructure (CNKI) and 
Wanfang med online databases between January 1, 2000, 
and June 28, 2018. We used the search terms (“beta-lac-
tamases/or carbapenemase, or carbapenem resistance/
resistant or drug resistance or carbapenemase* or car-
bapenem adj1 resist* or MBL or metallo-b-lactamase or 
VIM or NDM or OXA or oxacillinase or IMP or KPC or 
Klebsiella pneumoniae carbapenemase or OmpK”) AND 
(“Enterobacteriaceae/or enterobacteriaceae or Escheri-
chia/or Escherichia or Escherichia coli or Klebsiella or 
Klebsiella/Klebsiella pneumoniae/Klebsiella oxytoca”) 
AND (“China or Chinese”) AND (“neonate or newborn 
or infant”) for English databases. We used search terms 
(“Carbapenems or Carbapenem”) AND (“antibiotic 
resistance”) AND (“infant”, OR “neonatal”) for Chinese 
databases. We limited the searches to Chinese territo-
ries, including Taiwan, Hong Kong, and Macau. The full 
search strategy is available in Additional file 1: Table S1.
Inclusion and exclusion criteria
We include studies with original data on carbapenem-
resistant K. pneumoniae or E. coli sepsis in neonates, 
which contained any antimicrobial resistance (AMR) or 
genotype data, or showed the proportion of carbapenem 
resistant isolates of all Gram negative isolates, or clinical 
data (including patient demographics, underlying condi-
tions, and antibiotic treatment). We only included blood 
stream infections. The full details of inclusion and exclu-
sion criteria are presented in Additional file 2: Table S2.
Statistical analysis
Descriptive analysis was performed to investigate the dis-
tribution of genotype and MLST typing. Antimicrobial 
resistance rates were reported by median with interquar-
tile interval (IQI).
Results
Literature search and study selection
We identified 491 studies from Chinese and English 
database searches: 81 from CNKI, 214 from Wanfang 
med database, 96 from Pubmed/Medline and 100 from 
Embase (the flow chart is shown in Fig.  1). A total of 
17 studies met the inclusion criteria and were included 
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Records identified 214 studies from 
Wanfang database, 81 studies from 
CNKI, 96 studies from 
Pubmed/Medline, 100 studies from 
Embase 
(n =491)
Records after duplicates been removed
(n =375)
Title screened
(n = 375)
Abstract screened
(n =201)
Full-text articles assessed 
for eligibility
(n = 116)
Studies included in 
quantitative synthesis 
(systematic review)
(n = 17)
Title excluded
(n = 174)
Abstract excluded
(n = 85)
Full-text articles excluded
(n = 99)
Specimen not obtained 
from sterile site (n = 37)
Does not include study on 
carbapenem-resistant 
strains (n = 29)
Does not include study on 
Klebsiella pneumoniae or 
Escherichia coli (n = 8)
Does not include age 0-
30d neonates (n = 17)
Does not defined sample 
source (n = 4)
Data not from China 
(n = 3)
No full text (n = 1)
Fig. 1 Search strategy and process of study selection
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for final review, of these 11 (64.7%) reported genotype 
(including carbapenemase, β-lactamase genes and AmpC 
cephalosporinases genes) distribution and 9 (52.9%) 
reported AMR and clinical data. Only 6 studies reported 
treatment outcomes and gave the proportion of carbap-
enem-resistant isolates relative to all Gram-negative 
isolates. The full list of studies included in the review is 
available in Additional file 3: Table S3.
Demographics and clinical presentations of K. pneumoniae 
or E. coli infections
All 17 studies were from tertiary hospitals. Based on the 
Government economic divisions of China, 7 studies were 
from Eastern China, 6 studies from Central China, and 4 
studies from Western China. Only 9 of 17 studies reported 
clinical data, including patient demographics, underlying 
conditions, and antibiotic treatment. A total of 16 infants 
were included in these 9 studies. Eight of 16 patients 
were reported to have underlying conditions, including 6 
with lung disease, 2 with necrotizing enterocolitis (NEC) 
and 2 with recent surgery. Ten patients in these 9 stud-
ies reported antibiotic treatment: 5 received meropenem 
alone, 1 ceftazidime alone, 3 patients had received two 
antibiotics (piperacillin/sulbactam and ceftazidime; imi-
penem and amikacin; meropenem and ciprofloxacin) and 
1 patient had received more than three antibiotics. Eight 
patients in these 4 studies had received antibiotics prior to 
the onset of the relevant infection: 5 received meropenem, 
1 received panipenem and 2 didn’t report the type the 
antibiotics. Clinical treatment outcomes were reported in 
13 patients from 6 studies; 3 died and their deaths were 
attributed to the infection. Eleven patients of the six stud-
ies reported the source of infection. Ten patients (10/11, 
90.9%) were hospital-acquired infections, while only one 
was considered to be a vertical transmission.
The proportion of carbapenem resistant strains of all Gram 
negative strains
Only 6 studies (35%; 6/17) reported the proportion of 
carbapenem resistant isolates relative to all Gram-neg-
ative isolates causing sepsis. Overall, 39 (5.3%) carbap-
enem resistant K. pneumoniae and E. coli isolates were 
reported of out of a total of 740 Gram-negative isolates.
Antimicrobial resistance genotype and Multilocus 
Sequence Type (MLST)
Genotypic data were available for 21 isolates in 11 stud-
ies (20  K. pneumoniae, 1 E coli). The most commonly 
reported genotype was NDM-1 (81.0%, 17/21), followed 
by KPC-2 (9.5%, 2/21) and IMP-4 (9.5%, 2/21). 15 iso-
lates from 9 studies were tested β-lactamase genes, 66.7% 
(10/15) isolates carried TEM and SHV genotypes, and 
80.0% (12/15)carried CTX-M. 7 isolates from 5 studies 
were Amp C gene positive, and more than half of them 
were CMY-4/30 (57.1%; 4/7).
Antibiotic susceptibility results were reported from 19 
isolates in 9 studies. The resistance rates of carbapenem-
resistant Klebsiella pneumoniae (CRKP) and carbape-
nem-resistant Escherichia coli (CREC) to second-, third-, 
and fourth-generation cephalosporins were 100% (IQI 
100%–100%). All isolates were susceptible to colistin and 
fosfomycin (Table 1). MLST was identified for 14 isolates 
(13  K. pneumoniae and 1 E.coli) from 8 studies. ST105 
was the most common K. pneumoniae ST type (30.8%; 
4/13), followed by ST17 and ST 20 with 23.1% (3/13) and 
15.4% (2/13), respectively (Table 2).
Discussion
This is the first review of carbapenem-resistant Entero-
bacteriaceae (CRE) sepsis in Chinese neonates. Although 
the prevalence of adults and children with infections 
resistant to imipenem and meropenem reported by CHI-
NET in 2017 increased significantly, the samples were 
mainly derived from non-sterile body fluids, and the data 
for children were not broken down by age. This review 
has demonstrated that there are very limited recent data 
on carbapenem resistant isolates in neonates in China. 
CRKP is reported more than CREC. NDM-1 was the 
most commonly reported carbapenemase genotype, 
consistent with previous reports from Asia [11], but dif-
ferent to reports from the United States, where KPC is 
the most common genotype identified in children [12]. 
It is worth noting that the CLSI breakpoints for carbap-
enem changed in 2010 and in 2015, the CDC revised the 
definition for CRE. In this review, 12 studies provided 
CLSI reference standards. Among the 12 studies, only 
one adopted the CLSI standard of 2015, and the others 
adopted the CLSI standard of before 2015.
In 2017, the World Health Organization published a 
list of priority pathogens in order to inform global AMR 
research. CRE is one of the highest priority pathogens for 
the development of new antibiotics [13], but there are few 
new antibiotics available. Cefiderocol, is a novel catechol-
substituted siderophore cephalosporin with potent activity 
against meropenem-non susceptible Enterobacteriaceae 
[14], including metallo-β-lactamases (NDM-1, VIM, IMP). 
This is the most clinically advanced drug active against 
NDM carbapenem resistant organisms (CROs) infec-
tions [15], but no paediatric studies have yet commenced 
recruitment. The current standard treatment for NDM 
CRE infections is polymyxin based combination therapy 
[16]. However, polymixin E has complex pharmacoki-
netics requiring hydrolysis of the prodrug colistimethate 
sodium to colistin, making this less suitable for neonates 
and infants, and there are no pharmacokinetics data for 
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polymixin B in neonates [17]. Other older, off patent drugs 
that have potential activity against CROs include fosfo-
mycin and tigecycline, but again, these have no published 
PK data in neonates. In our study, we found that the cur-
rently reported carbapenem-resistant Enterobacteriaceae 
sepsis in neonate is mainly nosocomial infection. In view 
of the fact that there is no appropriate antibiotics to treat 
carbapenem resistant bacteria infection in neonates, it is 
very important to strengthen epidemiological surveillance, 
stringent standard infection control practices in healthcare 
settings, and to enhance the rational use of antibiotics.
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